Sulfated pentagalloyl glucose (Y-ART-3) inhibits HIV replication and cytopathic effects in vitro, and reduces HIV infection in hu-PBL-SCID mice

Antiviral Research

Volumn 30, Issue 2-3, 1996, Pages 95-108

  Nakashima, Hideki ^a   Ichiyama, Koji ^a   Hirayama, Fukushi ^b   Uchino, Keijiro ^c   Ito, Masahiko ^a   Saitoh, Takeshi ^b   Ueki, Masaaki ^d   Yamamoto, Naoki ^e   Ogawara, Hiroshi ^f  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Yamanouchi Pharmacentical Co Ltd   (Japan)

^c Kanagawa 243 0041   (Japan)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; DEXTRAN SULFATE; DIDANOSINE; IMMUNOGLOBULIN; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PERITONEUM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCID MOUSE; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN CELL; T LYMPHOCYTE; VIRUS ADSORPTION; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0029992379     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00903-5     Document Type: Article

References (25)

1. Abrams, D.I., Kuno, S., Wong, R., Jeffords, K., Nash, M., Molaghan, J.B., Gorter, R. and Ueno, R. (1989) Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann. Int. Med. 110, 183-188.
2. Aldrovandi, G.M., Feuer, G., Gao, L., Jamieson, B., Kristeva, M., Chen, I.S.Y. and Zack, J.A. (1993) The SCID-hu mouse as a model for HIV-1 infection. Nature 363, 732-736.
3. Barré-Sinoussi, F., Chermann, J.C., Rey, F., Nugeyre, M.T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vezinet Brun, F., Rouzioux, C. and Rozenbaum, W. (1983) Retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-870.
4. De Clercq, E. (1992) HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Human Retrovir. 8, 119-134.
5. De Clercq, E. (1991) Basic approaches to anti-retroviral treatment. J. Acquir. Immune Defic. Syndr. 4, 207-218.
6. Fischl, M.A., Richmann, D.D., Grieco, M.H., Gottlieb, M.S., Volberding, P.A., Laskin, O.L., Leedom, J.M., Groopman, J.E., Mildvan, D., Schooley, R.T., Jackson, G.G., Durack, D.T. and King, D. (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a doubleblind, placebo-controlled trial. N. Engl. J. Med. 317, 185-191.
7. Flexner, C., Barditch-Crovo, P.A., Kornhauser, D.M., Farzadegan, H., Nerhood, L.J., Chaisson, R.E., Bell, K.M., Lorentsen, K.J., Hendrix, C.W., Petty, B.G. and Lietman, P.S. (1991) Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob. Agents Chemother. 35, 2544-2550.
8. Larder, B.A., Graham, D. and Richman, D.D. (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734.
9. Lorentsen, K.J., Hendrix, C.W., Collins, J.M., Kornhauser, D.M., Petty, B.G., Klecker, R.W., Flexner, C., Eckel, R.H. and Leitman, P.S. (1989) Dextran sulfate is poorly absorbed after oral administration. Ann. Int. Med. 111, 561-566.
10. Mizuno, T., Uchino, K. Toukairin, T., Tanabe, A., Nakashima, H., Yamamoto, N. and Ogawara, H.(1992) Inhibitory effect of tannic acid sulfate and related sulfates on infectivity, cytopathic effect, and giant cell formation of human immunodeficiency virus. Planta Med. 58, 535-539.
11. Murakami, T., Nakashima, H., Ito, M. and Yamamoto, N. (1992) A novel coculture system for evaluating anti-HIV drugs. AIDS 20, 1279-1285.
12. Mosier, D.E., Gulizia, R.J., Baird, S.M., Wilson, D.B., Spector, D.H. and Spector, S.A.(1991) Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251, 791-794.
13. Nakashima, H., Inazawa, K., Ichiyama, K., Ito, M., Ikushima, N., Shoji, T., Katsuraya, K., Uryu, T., Yamamoto, N., Juodawlkis, A.S. and Schinazi, R.F. (1995) Sulfated alkyl oligosaccharides inhibit human immunodeficiency virus in vitro and provide sustained drug levels in mammals. Antiviral. Chem. Chemother. 6, 271-280.
14. Nakashima, H., Masuda, M., Murakami, T., Koyanagi, Y., Matsumoto, A., Fujii, N. and Yamamoto, N. (1992a) Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7] polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother. 36, 1249-1255.
15. Nakashima, H., Murakami, T., Yamamoto, N., Sakagami, H., Tanuma, S., Hatano, T., Yoshida, T. and Okuda, T. (1992b) Inhibition of human immunodeficiency viral replication by tannins and related compounds. Antiviral Res. 18, 91-103.
16. Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J. and De Clercq, E. (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20, 309-321.
17. Ratner, L., Haseltine, W., Patarca, R., Livak, K.J., Starcich, B., Josephs, S.F., Doran, E.R., Rafalski, J.A., Whitehorn, E.A., Baumeister, K., Ivanoff, L., Petteway S.R, Jr., Pearson, M.L., Lautenberger, J.A., Papas, T.S., Ghrayeb, J., Chang, N.T., Gallo, R.C. and Wong-StaaI F. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313, 277-278.
18. Richman, D.D., Fischl, M.A., Grieco, M.H., Gottlieb, M.S., Volberding, P.A., Laskin, O.L., Leedom, J.M., Groopman, J.E., Mildvan, D., Hirsch, M.S., Jackson, G.G., Durack, D.T., Phil, D. and Nusinoff-Lehrman, S. (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex; a double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 192-197.
19. + cells. J. Acquir. Immune Defic. Syndr. 2, 10-15.
20. Shimizu, N., Naoe, T., Kawazoe, Y., Sakagami, H., Nakashima, H., Murakami, T. and Yamamoto, N. (1993) Lignified materials as medicinal resources. VI. Anti-HIV activity of dehydrogenation polymer of p-coumaric acid, a synthetic lignin, in a quasi-in-vivo assay system as an intermediary step to clinical trials. Biol. Pharm. Bull. 16, 434-436.
21. Tochikura, T.S., Nakashima, H., Tanabe, A. and Yamamoto, N. (1988) Human immunodeficiency virus (HIV)-induced cell fusion: quantification and its application for the simple and rapid screening of anti-HIV substances in vitro. Virology 164, 542-546.
22. Toukairin, T., Uchino, K., Mizuno, T., Nakashima, H., Yamamoto, N. and Ogawara, H. (1992) New substances against human immunodeficiency virus: sulfated 5'-nucleotidase inhibitory polyphenols. Chem. Pharm. Bull. 40, 802-804.
23. Yarchoan, R., Mitsuya, H., Myers, C.E. and Broder, S. (1989a) Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 321, 726-738.
24. Yarchoan, R., Mitsuya, H., Thomas, R.V., Pluda, J.M., Hartman, N.R., Perno, C-F., Marczyk, K.S., Allain, J-P., Johns, D.G. and Broder, S. (1989b) In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science 245, 412-417.
25. Witvrouw, M., Baba, M., Balzarini, J., Pauwels, R. and De Clercq, E. (1990) Establishment of a bioassay to determine serum levels of dextran sulfate and pentosan polysulfate, two potent inhibitors of human immunodeficiency virus. J. Acquir. Immune. Defic. Syndr. 3, 343-346.